Browse
Submit Data
Databases
API
Help

Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

12 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene expression in human post-mortem brain samples from schizophrenic subjects and matched controls

ABSTRACT: This laboratory focuses on the molecular mechanisms of neuropsychiatric and neurodegenerative disorders Gene expression patterns from the pefrontal cortical region (Brodmann Area 46) of subjects with schizophrenia and age- and sex-match control subjects was analyzed. The prefrontal cortex was chosen since it is a primary brain region implicated in the pathophysiological of schizophrenia. Furthermore, this region was used in our previous proteomics studies, allowing for the direct comparison of changes in protein levels to gene expression results. 16 schizophrenic subjects were studied, consisting of 8 subjects with duration of illness (DOI) < 5 years and 8 subjects with DOI > 22 years. 16 age- and sex-matched controls were also studied. Gene expression profiles were analyzed from individual subjects; a total of 32 samples were hybridized to the custom designed CFG GLYCOv2 glycogene array.

ORGANISM(S): Homo sapiens

SUBMITTER: Steven Head

PROVIDER: E-GEOD-27356 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Similar Datasets

Comparison of post-mortem tissue from Brodman Brain BA22 region between schizophrenic and control patients

Project description:Transcriptional analysis of the superior temporal cortex (BA22) in schizophrenia: Pathway insight into disease pathology and drug development Schizophrenia is a highly debilitating psychiatric disorder which is known to have heritable genetic and environmental components. To gain some insight into the mechanisms underpinning both positive and negative symptoms of the disease, we determined the genome wide expression of mRNA transcripts in post-mortem tissue from the superior temporal cortex (Brodmann Area 22, BA22) in schizophrenic and control patients. The BA22 region is known to mediate the positive pathophysiology of schizophrenia; we compared this to the anterior prefrontal cortex (BA10) from the same subjects, which is known to mediate negative symptoms. Following adjustments for confounding clinical, sample and experimental sources of variation, we carried out gene set enrichment analysis in each region using pathway data. We identified an over-representation of genes involved in cytoskeletal remodelling, neurodevelopment, cell adhesion, cellular signalling, neurotransmission and autophagy. Collectively our analysis indicates a disruption of processes underpinning synaptic plasticity in both regions. Region-specific changes support the dysregulation of distinct pathways in the BA10 and BA22 regions. This may highlight new therapeutic opportunities to treat both negative and positive symptoms of the disease. Post-mortem derived BA22 tissue from schizophrenic and control patients were compared. Age, gender, post-mortem delay and pH of brain lysates data were also captured.

2011-12-31 | E-GEOD-21935 | biostudies-arrayexpress

Comparison of post-mortem tissue from brain BA10 region between schizophrenic and control patients.

Project description:Analysis of gene expression in two large schizophrenia cohorts identifies multiple changes associated with nerve terminal function. Schizophrenia is a severe psychiatric disorder with a world-wide prevalence of 1%. The pathophysiology of the illness is not understood, but is thought to have a strong genetic component with some environmental influences on aetiology. To gain further insight into disease mechanism, we used microarray technology to determine the expression of over 30 000 mRNA transcripts in post-mortem tissue from a brain region associated with the pathophysiology of the disease (Brodmann area 10: anterior prefrontal cortex) in 28 schizophrenic and 23 control patients. Post-mortem derived BA10 tissue from 28 schizophrenic and 23 control patients were compared. Age, gender, post-mortem delay and pH of brain lysates data were also captured.

2009-08-13 | E-GEOD-17612 | biostudies-arrayexpress

Comparison of post-mortem tissue from brain BA10 region between schizophrenic and control patients.

2009-08-13 | GSE17612 | GEO

Comparison of post-mortem tissue from Brodman Brain BA22 region between schizophrenic and control patients

2011-12-31 | GSE21935 | GEO

Comparing Control and Schizophrenic hiPSC-derived Neurons

Project description:Schizophrenia is a debilitating neurological disorder for which no cure exists. Few defining characteristics of schizophrenic neurons have been identified and the molecular mechanisms responsible for schizophrenia are not well understood, in part due to the lack of patient material for study. Human induced pluripotent stem cells (hiPSCs) offer a new strategy for studying schizophrenia. We have created the first cell-based human model of a complex genetic psychiatric disease by generating hiPSCs from schizophrenic patients and subsequently differentiating these cells to hiPSC-derived neurons in vitro. Schizophrenic hiPSC-derived neurons showed diminished neuronal connectivity in conjunction with decreased neurite number, PSD95-protein levels and glutamate receptor expression. Gene expression profiles of schizophrenic hiPSC-derived neurons identified altered expression of many components of the cAMP and WNT signaling pathways. Key cellular and molecular elements of the schizophrenic phenotype were ameliorated following treatment of schizophrenic hiPSC-derived neurons with the antipsychotic loxapine.

2011-05-01 | GSE25673 | GEO

Extension of glycogene expression pattern analysis in the prefrontal cortical region of Schizophrenic human post-mortem brain samples

Project description:This laboratory focuses on the molecular mechanisms of neuropsychiatric and neurodegenerative disorders Extension of previous studies investigating Glyco-Gene Expression in Schizophrenia (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE27356 ). From previous analyses, a group of 9 genes associated with the biosynthesis of glycosphingolipids were identified as altered in subjects with schizophrenia, with most differences detected in subjects with short DOI and not in chronic illness. The enzyme expression changes are of particular interest as they are important to the synthesis of cerebrosides and sulfatides, which are enriched in membranes making up myelin. There are known deficits in myelin and white matter in schizophrenia so changes in these enzymes may represent a mechanism accounting for these deficits. Furthermore, clusters of co-regulated genes were identified using new software for weighted gene co-networks. This may represent the first molecular definition of different subtypes of schizophrenia, a very heterogeneous psychiatric disorder. For this follow up study, microarray analyses experiments were performed on an additional cohort of subjects with schizophrenia in order to, 1) Assess how this group of glycosphingolipid-related genes is altered in disease and control states, and 2) Further determine if co-regulated genes will cluster in the new cohort, which will consist of subjects with a range of durations of illness. For these studies, 32 human samples (16 control and 16 Schizophrenic) were labeled and hybridized to 26 GLYCOv2 arrays

2011-03-02 | E-GEOD-27601 | biostudies-arrayexpress

Comparing Control and Schizophrenic hiPSC-derived Neurons

2011-05-01 | E-GEOD-25673 | biostudies-arrayexpress

Epigenome analysis of normal and schizophrenic samples

Project description:We analyzed fresh frozen post-mortem brain tissue from a cohort of 73 schizophrenic and 52 control samples, using the Illumina Infinium HumanMethylation450 Bead Chip, to investigate genome-wide DNA methylation patterns in patients diagnosed with schizophrenia.

2019-03-21 | GSE128601 | GEO

Gene Expression Profiles in BA46 of Subjects with Schizophrenia and Matched Controls

Project description:Results from clinical and imaging studies provide evidence for changes in schizophrenia with disease progression, however, the underlying molecular differences that may occur at different stages of illness have not been investigated. To test the hypothesis that the molecular basis for schizophrenia changes from early to chronic illness, we profiled genome-wide expression patterns in prefrontal cortex of schizophrenic subjects at different stages of illness, along with their age- and sex-matched controls. Results show that gene expression profiles change dramatically depending on the stage of illness, whereby the greatest number and magnitude of gene expression differences were detected in subjects with short-term illness (â?¤ 4 years from diagnosis). Comprehensive pathways analyses revealed that each defined stage of illness was associated with dysfunction in both distinct, as well as overlapping systems. Short-term illness was particularly associated with disruptions in gene transcription, metal ion binding, RNA processing and vesicle-mediated transport. In contrast, long-term illness was associated with inflammation, stimulus-response and immune functions. We validated expression differences of 12 transcripts associated with these various functions by real-time PCR analysis. While only four genes, SAMSN1, CDC42BPB, DSC2 and PTPRE, were consistently expressed across all groups, there was dysfunction in overlapping systems among all stages, including cellular signal transduction, lipid metabolism and protein localization. Our results demonstrate that the molecular basis for schizophrenia changes from early to chronic stages, providing evidence for a changing nature of schizophrenia with disease progression. N=30 subjects with schizophrenia and n=29 age- and sex-matched controls. Age range = 18-81 years

2010-04-12 | E-GEOD-21138 | biostudies-arrayexpress

Extension of glycogene expression pattern analysis in the prefrontal cortical region of Schizophrenic human post-mortem brain samples

2011-03-02 | GSE27601 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data